European blood safety techs market set to exceed $520m by 2013
This article was originally published in Clinica
Europe’s blood pathogen inactivation market is set to reach an estimated $521.5m by 2013, according to analysts Frost & Sullivan, from around $238.5m in 2009. The impact of “remarkable advances” in the prevention of transfusion-transmitted diseases has been slowed by an excessively reactive approach to transfusion risk, argue the authors of a report called European Blood Pathogen Inactivation Market, published today. However, the continued emergence and re-emergence of transfusion-transmitted infections promises “very good potential for growth”, they claim.